Co-Diagnostics (CODX) Price & Analysis

Compare

1,638 Followers

CODX Stock Chart & Stats

$0.35

-$0.07(-8.42%)

At close: Jan 08 4:00 PM EST

$0.35

-$0.07(-8.42%)

Day’s Range― - ―

52-Week Range$0.23 - $1.55

Previous CloseN/A

Volume146.43K

Average Volume (3M)10.09M

Market Cap

$23.53M

Enterprise Value-$2.38M

Total Cash (Recent Filing)$11.44M

Total Debt (Recent Filing)$1.47M

Price to Earnings (P/E)―

Beta1.47

Next Earnings

Mar 19, 2026

EPS Estimate

-0.12

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.16

Shares Outstanding60,892,582

10 Day Avg. Volume1,334,715

30 Day Avg. Volume10,088,102

Financial Highlights & Ratios

PEG Ratio-0.18

Price to Book (P/B)0.42

Price to Sales (P/S)5.81

P/FCF Ratio-0.76

Enterprise Value/Market Cap-0.10

Enterprise Value/Revenue-4.69

Enterprise Value/Gross Profit-13.78

Enterprise Value/Ebitda0.07

Forecast

1Y Price Target

$1.50

Price Target Upside328.57% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering2

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Market ExpansionThe Indian market presents significant opportunities for Co-Diagnostics through the CoSara joint venture, with potential for 30,000 MTB test placements at primary health centers.

Product InnovationCo-Diagnostics' PCR Pro is a desktop RT-PCR device that offers diagnostic performance comparable to higher-priced devices but at a significantly lower cost.

Strategic PartnershipsCo-Diagnostics has signed an agreement with Arabian Eagle Manufacturing to commercialize Co-Dx technologies across Saudi Arabia and 18 MENA nations.

Bears Say

Capital RequirementsThe company may need to raise additional capital at the current price level, which could impact shareholder value.

Market Success UncertaintyThe company faces risks related to the potential failure to achieve commercial success with its products.

Regulatory RisksThere are risks associated with the potential failure to secure regulatory clearance for Co-Diagnostics' clinical evaluations.

Co-Diagnostics News

Co-Diagnostics initiated with a Buy at Maxim

Maxim initiated coverage of Co-Diagnostics (CODX) with a Buy rating and $1.50 price target Published first on TheFly...

17d ago

CODX

Co-Diagnostics Approves Reverse Stock Split Proposal

Co-Diagnostics ( ($CODX) ) has shared an update. On December 5, 2025, Co-Diagnostics, Inc. held a special meeting...

8d ago

CODX

Coterra, Ovintiv, Nektar, Co-Diagnostics, Fluence: Trending by Analysts

Analysts are intrested in these 5 stocks: ( ($CTRA) ), ( ($OVV) ), ( ($NKTR) ), ( ($CODX)...

14d ago

OVV

CODX

Co-Diagnostics Earnings Call: Strategic Moves Amid Financial Struggles

Co-Diagnostics (($CODX)) has held its Q3 earnings call. Read on for the main highlights of the call. The...

29d ago

CODX

Co-Diagnostics Expands Global Reach and Innovates with AI

Co-Diagnostics ( ($CODX) ) has released its Q3 earnings. Here is a breakdown of the information Co-Diagnostics presented...

29d ago

CODX

CODX Upcoming Earnings Report: What to Expect?

Co-Diagnostics (CODX) is scheduled to report 3rd quarter earnings on 11/13/2025, after the market closes. Regarding Q3 estimates,...

1M ago

CODX

Co-Diagnostics selects Maxim Group as financial advisor for CoSara Diagnostics

Co-Diagnostics (CODX) announced that it has engaged Maxim Group as its exclusive financial advisor to assist the Company...

1M ago

CODX

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Getty Images (GETY) 49.86%...

1M ago

IEP

NNE

Co-Diagnostics forms new AI business unit

Co-Diagnostics (CODX) announced the formation of a newly organized, artificial intelligence business unit, led by Chief Technology &...

1M ago

CODX

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Co-Diagnostics (CODX) 108.22% +12.33,...

1M ago

LGO

Co-Diagnostics Announces $7M Securities Purchase Agreement

Co-Diagnostics ( ($CODX) ) has issued an announcement. On October 28, 2025, Co-Diagnostics, Inc. announced a Securities Purchase...

1M ago

CODX

Co-Diagnostics announces closing of $7M registered direct offering

Co-Diagnostics (CODX) announced the closing of its previously announced offering of 12,727,272 shares of common stock at an...

1M ago

CODX

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: Beyond Meat (BYND) 46.53%...

2M ago

BTQ

SLS

Co-Diagnostics announces pricing of $7M registered direct offering

Co-Diagnostics (CODX) announced that it has entered into a securities purchase agreement with several institutional investors for the...

2M ago

CODX

CODX FAQ

What was Co-Diagnostics Inc’s price range in the past 12 months?

Co-Diagnostics Inc lowest stock price was $0.23 and its highest was $1.55 in the past 12 months.

What is Co-Diagnostics Inc’s market cap?

Co-Diagnostics Inc’s market cap is $23.53M.

When is Co-Diagnostics Inc’s upcoming earnings report date?

Co-Diagnostics Inc’s upcoming earnings report date is Mar 19, 2026 which is in 96 days.

How were Co-Diagnostics Inc’s earnings last quarter?

Co-Diagnostics Inc released its earnings results on Nov 13, 2025. The company reported -$0.16 earnings per share for the quarter, beating the consensus estimate of -$0.19 by $0.03.

Is Co-Diagnostics Inc overvalued?

According to Wall Street analysts Co-Diagnostics Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Co-Diagnostics Inc pay dividends?

Co-Diagnostics Inc does not currently pay dividends.

What is Co-Diagnostics Inc’s EPS estimate?

Co-Diagnostics Inc’s EPS estimate is -0.12.

How many shares outstanding does Co-Diagnostics Inc have?

Co-Diagnostics Inc has 60,892,582 shares outstanding.

What happened to Co-Diagnostics Inc’s price movement after its last earnings report?

Co-Diagnostics Inc reported an EPS of -$0.16 in its last earnings report, beating expectations of -$0.19. Following the earnings report the stock price went down -10.811%.

Which hedge fund is a major shareholder of Co-Diagnostics Inc?

Currently, no hedge funds are holding shares in CODX

Company Description

Co-Diagnostics Inc

Co-Diagnostics, Inc. (CODX) is a biotechnology company focused on the development and commercialization of molecular diagnostic tests. The company specializes in the design and manufacture of diagnostic solutions for infectious diseases, including COVID-19, and other conditions, utilizing its proprietary CoPrimer technology. The company operates primarily in the healthcare sector, providing innovative tools that enhance the accuracy, speed, and affordability of diagnostic testing.

Co-Diagnostics (CODX) Earnings & Revenues

Historic Earnings Reports

CODX Earnings Call

Q3 2025

0:00 / 0:00

Earnings Call Sentiment|Neutral

The earnings call highlighted the company's strategic initiatives and international expansion efforts as major drivers of future growth. However, significant financial challenges remain, with declining revenue and continued net losses, albeit with improved operational efficiency.View all CODX earnings summaries

CODX Stock 12 Month Forecast

Average Price Target

$1.50

▲(328.57% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","-1":"-$1","-0.25":"-$0.25","0.5":"$0.5","1.25":"$1.25"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$1.50</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":1.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$1.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[-1,-0.25,0.5,1.25,2],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2024","6":"Apr<br/>2025","9":"Jul<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.46,0.54,0.62,0.7,0.78,0.8600000000000001,0.94,1.02,1.1,1.18,1.26,1.34,1.42,{"y":1.5,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.46,0.54,0.62,0.7,0.78,0.8600000000000001,0.94,1.02,1.1,1.18,1.26,1.34,1.42,{"y":1.5,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,0.46,0.54,0.62,0.7,0.78,0.8600000000000001,0.94,1.02,1.1,1.18,1.26,1.34,1.42,{"y":1.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.05,"date":1717200000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.11,"date":1722470400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":1.21,"date":1730419200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.94,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.75,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.5,"date":1740787200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.33,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.36,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.26,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.28,"date":1751328000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.25,"date":1754006400000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.35,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 0,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":0.46,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >